Drugs / ALZ002 DS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04392830 | May 2020 → Apr 2021 | — | AnnJi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALZ002 DS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04392830 ↗ |
| Route | Oral | “Administered orally” NCT04392830 ↗ |